NDAINJECTIONINJECTABLEPriority Review
Approved
Dec 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEUTREXIN (trimetrexate glucuronate) is an injectable antimetabolite approved in 1993 for treating Pneumocystis jirovecii pneumonia (PCP), particularly in immunocompromised patients who cannot tolerate standard therapies. It functions as a dihydrofolate reductase inhibitor, disrupting DNA synthesis in susceptible organisms. The drug is administered intravenously and requires concurrent leucovorin rescue therapy to mitigate toxicity.
LOE Approaching
With LOE approaching and minimal Part D visibility, this product likely operates with a lean, specialized team focused on niche hospital and specialty pharmacy channels.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NEUTREXIN offers limited career growth opportunity due to zero linked job postings and LOE-approaching status; this product is suitable for professionals seeking to manage legacy/niche brands or transition roles. Roles on this team typically involve high-touch specialist engagement and regulatory compliance rather than broad commercial expansion.
Product Manager (Specialty)
Worked on NEUTREXIN at Immune-Onc Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.